🔗 Share this article

As the United States proceeds with historic adjustments to its vaccine schedules, one figure has surfaced unexpectedly: Tracy Beth Høeg, a Danish American physician and public health researcher who initially gained attention by expressing skepticism about Covid vaccinations in the pandemic and has concentrated on possible deaths following Covid vaccination in her brief tenure at the FDA.

Planned Shifts to Childhood Immunization Schedule

Health officials had intended to unveil sweeping revisions to the pediatric vaccine schedule earlier this month, bringing the US with the Danish immunization schedule, according to reports – a major change that would put the US at odds with a large portion of the global community with insufficient data for benefit. This reveal has been pushed back until the new year.

In place of Vinay Prasad, Dr. Høeg is set to speak at the gathering. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the center this year.

A Shift at the Regulatory Body

This interim role might represent a closer partnership between the pharmaceutical and biologics divisions as Høeg and Prasad solidify control at the FDA – and it points to a increased emphasis upon reevaluating long-standing vaccines at the FDA.

The new acting director has repeatedly called for halting some pediatric vaccine recommendations in the US to become more in line with the Danish model, a nation with comprehensive healthcare and a number of inhabitants roughly the size of the state of Wisconsin.

In her initial comments, she has kept her attention on vaccination policy – typically the purview of Dr. Prasad, director of the FDA’s CBER – rather than pharmaceutical oversight.

Concerns Over Qualifications

Dr. Høeg has no apparent background in pharmaceutical research, regulation or leadership, which has been standard for past leaders of the biologics center. She has been employed at the FDA as a top consultant to the agency head and the vaccine center since spring.

“She appears not to have the necessary background” for leading the pharmaceutical oversight division, stated Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in running a large organization. She lacks background in drug approvals.”

Former commissioners of the center would “grasp laws and regulations and the underlying principles of pharmaceutical innovation”, said Janet Woodcock. “Objectively, she has not acquired the sort of resume that prior appointees who headed CBER have had.”

The drug center has an vast workload at the agency, the former commissioner stated.

“Everybody just focuses on the innovative therapies, but the generic program approves numerous generic drugs. There is also a biosimilars division, OTC medication office and other areas, and all of those need to be looked after,” she explained. “The thing you overlook, that’s the thing that I always told people is going to bite you.”

Furthermore, a substantial leadership element to the job, which oversees over 5,000 personnel. “It is a massive administrative position, if you perform it correctly,” she said.

Official Statement and Contentious Programs

Regarding inquiries about Høeg’s qualifications and whether this appointment indicates more teamwork among agency officials on vaccines, a spokesperson responded that the “inquiries are based on incorrect presumptions”.

“This background matches the duties of her job,” the representative said, pointing to the period Dr. Høeg spent counseling the agency head on “drug safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Dr. Høeg takes over the commissioner’s new priority voucher program, a contentious rapid medication authorization process that allegedly concerned her predecessors. “How are these therapies being selected for this fast-track system? Who takes the decisions?” Dr. Howard said. “There’s a lot of confidentiality occurring at the regulatory body right now.”

Overall, he said, “the FDA seems to be moving towards more relaxed oversight of pharmaceuticals, except for shots.”

Documented Track Record on Immunizations

Regarding immunizations, Dr. Høeg has a more established, if concerning, track record, Howard have noted. She released a analysis using non-validated volunteer-provided data to assess the rate of heart inflammation after Covid vaccination. She counseled the Florida surgeon general Dr. Joseph Ladapo, who allegedly have altered data to imply COVID-19 vaccines are more dangerous than they are.

Part of her “desired changes” for the incoming administration included changing rules for recently developed shots and ending “non-essential” immunizations, she said after the election on a podcast. At the agency, Dr. Høeg has allegedly suggested excluding adolescent males from receiving Covid vaccinations.

“She is an all-around ideologue who starts off with her preconceived notions and works backwards to accommodate the science in a very deceptive, fraudulent manner,” Howard stated.

Consolidating Power and a “Push for Payback”

Høeg joined fellow contrarians, {like|